Status:
UNKNOWN
Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy
Lead Sponsor:
Xiangya Hospital of Central South University
Conditions:
Alzheimer Disease 3
Epilepsy
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Participants will perform Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Alzheimer's disease assessment scale-cognitive section (ADAS-Cog),...
Eligibility Criteria
Inclusion
- Clinically diagnosed as Alzheimer's disease and treated with cholinesterase inhibitors;
- New seizures or subclinical epileptic discharges;
- Mini-Mental State Examination score ≥ 18 points, and/or Clinical Dementia Rating (CDR) score \< 2 points;
- Sign the informed consent form.
Exclusion
- Suffering from syncope, transient ischemic attack, hysteria attack, migraine and other transient brain dysfunction;
- Serious medical disease (especially atrioventricular block) or mental illness;
- There are structural abnormalities related to epilepsy in other brain regions of imaging
Key Trial Info
Start Date :
July 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT05969054
Start Date
July 5 2023
End Date
December 31 2025
Last Update
August 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangya Hospital of Central South University
Changsha, Hunan, China, 410008